Stroke, new approach of treatment

dc.contributor.advisorPórszász, Róbert
dc.contributor.advisordeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.contributor.authorMeital-Meslati, Aaron
dc.contributor.departmentDE--Általános Orvostudományi Karhu_HU
dc.contributor.opponentSzentmiklósi, József András
dc.contributor.opponentDrimba, László
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézethu_HU
dc.contributor.opponentdeptKenézy Kórház Aneszteziológiai és Intenziv Therápiás Osztályhu_HU
dc.date.accessioned2016-09-15T12:59:10Z
dc.date.available2016-09-15T12:59:10Z
dc.date.created2016-05-05
dc.description.abstractStroke is the second most common cause of death and major cause of disability worldwide. Ischemic stroke is the most common type of stroke and caused by acute blockage occurs of arterial blood flow to the brain. One important survival mechanism of the cell is to defense the energy exhaustion and metabolic processes under cerebral ischemia, and it also determines the outcome of acute brain injury caused by ischemic stroke. Enhancing the defense mechanisms against stroke injury is considered as a major target for development of new therapies for stroke prevention and treatment. Such key element can be the Nicotinamide phosphoribosyltransferase (Nampt), it is the rate limiting enzyme in mammalian NAD+ biosyntheses. Nampt converts nicotinamide into nicotinamide mononucleotide (NMN), which is subsequently converted to nicotinamide adenine dinucleotide (NAD) + , it was reported as a visceral fat-derived adipokine and renamed visfatin.hu_HU
dc.description.courseáltalános orvoshu_HU
dc.description.courselangangolhu_HU
dc.description.degreeegységes, osztatlanhu_HU
dc.format.extent38hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/230471
dc.language.isoenhu_HU
dc.subjectStrokehu_HU
dc.subject.dspaceDEENK Témalista::Orvostudományhu_HU
dc.titleStroke, new approach of treatmenthu_HU
Fájlok